

19

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/17, A23L 1/305, C07K 14/47		A1	(11) International Publication Number: WO 95/32727
			(43) International Publication Date: 7 December 1995 (07.12.95)

(21) International Application Number: PCT/US95/03628	(81) Designated States: AU, CA, JP, MX, NZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).		
(22) International Filing Date: 27 March 1995 (27.03.95)			
(30) Priority Data:			
249,554 26 May 1994 (26.05.94) US			
249,555 26 May 1994 (26.05.94) US			
(71) Applicant: ABBOTT LABORATORIES [US/US]; Dept. 377/AP6D, 200 Abbott Park Road, Abbott Park, IL 60064-3537 (US).			
(72) Inventors: MUKERJI, Pradip; 1069 Arcaro Drive, Gahanna, OH 43230 (US). SEO, Amanda, Eun-Yeong; 4157 Silver Rod Lane, Gahanna, OH 43230 (US). ANDERSON, Steven, Neal; 401 Stonemill Road, Pickerington, OH 43147 (US). SCHALLER, Joseph, Paul; 1547 Noe Bixby Road, Columbus, OH 43232 (US).			
(74) Agents: DRAYER, Lonnie, R. et al.; Abbott Laboratories, Dept. 108140/DS1, 625 Cleveland Avenue, Columbus, OH 43215-1724 (US).			

(54) Title: INHIBITION OF INFECTION OF MAMMALIAN CELLS BY RESPIRATORY SYNCYTIAL VIRUS

(57) Abstract

The infection of mammalian cells by RSV may be inhibited by native human β -casein, a recombinant form of human β -casein, and hydrolysates of both. The human β -casein or hydrolysate may be contained in a liquid enteral nutritional product such as an infant formula. The enteral nutritional product may be used, for example, in the prevention and treatment of respiratory tract infection in infants. The human β -casein or hydrolysate may also be administered as a throat spray or nasally using drops or a spray.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

INHIBITION OF INFECTION OF MAMMALIAN CELLS BY RESPIRATORY SYNCYTIAL VIRUS

The present invention relates generally to inhibiting the infection of mammalian cells by Respiratory Syncytial Virus, and more specifically to the use of native or recombinant human β -casein and hydrolysates thereof for inhibiting the infection of mammalian cells by Respiratory Syncytial Virus.

Respiratory Syncytial Virus (RSV) is the single most frequent cause of acute respiratory tract infection in infants and children. Infants less than six months of age are most frequently and seriously affected. In most immunologically normal subjects, infection with RSV is limited to the respiratory mucosa, and is associated with the development of bronchiolitis, pneumonia and reactive airway disease. RSV infection in immunocompromised subjects has until recently been associated with increased mortality in infants and increased morbidity in other age groups. It has recently been reported in PEDIATRIC NOTES, Vol. 18, No. 14, January 27, 1994, that periods of high incidence of acute respiratory disease and numbers of deaths in elderly people were followed within 2-3 weeks by reports of high numbers of RSV or influenza virus isolates. The analyses indicate that RSV is as important as influenza viruses in causing morbidity and deaths among the elderly.

It has been reported that some respiratory disease may be prevented by breast feeding, and that "bronchiolitis of infants due to respiratory syncytial virus is less frequent in breast fed than in artificially fed infants". While human breast milk can contain antibodies to RSV, it has been found that milk also has antiviral activity that is not due to antibodies. It has been theorized that this effect "may be produced by certain polysaccharides which are found on a number of different molecular constituents of milk." Tyrrell, "BREAST FEEDING AND VIRUS INFECTIONS", THE IMMUNOLOGY OF INFANT FEEDING, edited by A. W. Wilkinson, Plenum Press, New York, NY pages 55-62 (1981).

Okamoto, et al., "Antiviral Factors in Human Milk: Implications in Respiratory Syncytial Virus Infection". ACTA PAEDIATRICA SCANDANAVICA SUPPLEMENT, 351:137-143 (1989) disclose that while the mechanisms of protective immunity to RSV had not been clearly defined, immunity acquired

transplacentally or via breast feeding has been suggested to reduce the risk of lower respiratory tract disease. However, this publication focuses upon the role of antibodies transmitted in breast milk or the possible role of breast milk in modulating an infant's RSV immune response.

Laegreid et al., "Neutralizing Activity in Human Milk Fractions against Respiratory Syncytial Virus", ACTA PAEDIATRICA SCANDANAVICA, 75:696-701 (1986) reports a study which confirms that human milk may contain RSV-neutralizing activity of a non-immunoglobulin nature as well as RSV-specific antibody. However, the identity and mechanism of the non-immunoglobulin anti-RSV component of human milk is not identified. It is important though to note that Laegreid et al. disclose that RSV-neutralizing components from breast milk may reach an infant's respiratory tract directly as a result of regurgitation and inhalation of milk during and after feeding. The mucosa of the respiratory tract may gain direct protection in this way.

WO 91/06308 filed by Andersson et al. for "ANTIBACTERIAL COMPOSITION", and a published article by the same authors (Aniansson et al., "Anti-adhesive activity of human casein against *Streptococcus pneumoniae* and *Haemophilus influenzae*", MICROBIAL PATHOGENESIS, 8:315-323 (1990) disclose the use of a milk fraction having a molecular weight of at least 5,000 daltons for "therapeutic prophylactic, and/or diagnostic use in infections caused by *S. pneumoniae* and/or *H. influenzae*", but it is suggested in these publications that the beneficial effect is provided by kappa-casein. However, the present invention relates to the use of native or recombinant human β -casein and hydrolysates of both to inhibit RSV infections.

WO93/04172 relates to a DNA sequence encoding human β -casein, but does not disclose the capacity of either native or recombinant human β -casein to inhibit the attachment of RSV to human cells.

WO91/08675 discloses an infant formula which contains recombinant forms of both human alpha-lactalbumin and human β -casein. However, this publication discloses only that these human milk proteins will "give a simulated human mother's milk formula that does not exhibit the allergenic properties associated with formulas based on cow or other foreign protein." (page 3, lines 20-22). The use of human β -casein to inhibit the attachment of RSV to human cells is not taught or suggested in said publication.

The two assays (a HEp-2 cell assay and a LLC-MK2 cell assay) which were used for determining the bioactivity of β -casein are described below. These assays have not been published heretofore, although the HEp-2 cell

assay was based upon established methodology.

MATERIALS USED IN BOTH ASSAYS

Native Human β -Casein

β -casein isolated from human milk was purchased from Symbicom AB, P.O. Box 1451, S-901 24 Umea, Sweden.

Recombinant Human β -Casein

Applicants obtained β -casein cDNA and the expression system from Symbicom AB, P.O. Box 1451, S-901 24 Umea, Sweden. The human β -casein cDNA used had been previously cloned and sequenced by Lonnerdal et al.. Cloning and sequencing of a cDNA encoding human milk β -casein. (SEQ.ID NO: 1:) *Federation of European Biochemical Societies Letters* 269, 153-156 (1990). The recombinant human β -casein was obtained from *E. coli* and purified according to the method of Hansson et al.. "Expression of Human Milk β -Casein in *Escherichia coli*: Comparison of Recombinant Protein with Native Isoforms". *Protein Expression and Purification* 4, 373-381 (1993). To express human β -casein in *E. coli*, β -casein cDNA was cloned under control of a T7 promoter in two different expression vectors. One vector, pS26, was designed for intracellular expression. The other vector, pS28, has a signal sequence for extracellular expression. The procedure followed was substantially that described by Hansson et al.

Human β -casein cDNA was isolated by Hansson et al. as a 1.1-kb EcoRI fragment from a human lambda gt mammary gland library, and was subcloned into pUC19, which was designated pS21. The cDNA was modified by introduction of synthetic oligonucleotides in the 5' and 3' termini. To introduce a suitable cloning site in the 5' end, *Nde*I, a translational start, was inserted in front of the sequence encoding mature human β -casein. To adapt the initial part of the translated sequence to *E. coli* codon usage, six synthetic oligonucleotides were constructed and ligated. Also, *Pst*I and *Eco*RI sites were inserted in front of the *Nde*I site. The sequence of the synthetic fragment was 5' - CTGCAGAATTCATATGCGTGAAACCATCGAATCCCTGAGCTCGAGCGAAGAATCGATACCGAATACAAAAAGTTGAAAAAGTTAACACGAGGACCAGGATCC-3'. (SEQ ID NO: 2:) The protein encoding sequence is underlined. The synthetic fragment was cloned into *Pst*I/*Bam*HI-digested pUC19 resulting in plasmid pS24. To insert the rest of the β -casein

encoding sequence, a 303-bp *AccI/BgII* fragment was isolated and cloned into a *pUC18* derivative and designated plasmid *pS22*. Four synthetic oligonucleotides containing the sequence encoding the carboxy-terminal end and translation stop followed by *BamHI* and *EcoRI* sites were constructed resulting in the sequence 5' AGATCTACCCCTGTGA CTCAGCCACTTGCCCCAGTTCTATAACCCCATTAGTGTCTAATAAGGATCCGAATT-3'.

(SEQ ID NO: 3:) where the protein encoding sequence is underlined. The synthetic fragment was cloned into *BgIII/EcoRI* digested *pS22*, resulting in plasmid *pS23*. To obtain the recombinant modified β -casein encoding fragment, three fragments were ligated: an 89-bp *PstI/AvaII* fragment from *pS24*; a 197-bp *AvaII/AccI* fragment from *pS21*; and *PstI/AccI* digested *pS23*. The resulting plasmid *pS25* was digested with *NdeI/BamHI* and a 641-bp fragment was isolated and cloned into the vector *pET-3a*. The resulting expression vector was designated *pS26*.

In order to construct a vector mediating extracellular expression, the *E. coli* signal sequence of the enterotoxin STII gene was introduced in front of the β -casein encoding sequence. A modified STII sequence with *NcoI*- and *NdeI*-compatible ends and an internal *ClaI* site was obtained by using a synthetic oligonucleotide, 5'-CATGAAAAAGAATATCGCATTCTTGCATCGATGTTCGTTT TTTCTATTGCTACAAATGCATATG-3' (SEQ ID NO: 4:). To insert the signal sequence in front of the β -casein encoding sequence, *pS25* was digested with *AvaI/EcoRI* and a 619-bp fragment was isolated. This fragment was ligated with a synthetic oligonucleotide fragment, 5'CATATGCACGTGAAACCATCGAATCCCTGAGCTCGAG-3' (SEQ ID NO: 5:), and *NdeI/EcoRI*-digested *pUC19*. The resulting plasmid was designated *pS27*. The final expression vector, *pS28*, was constructed by ligating three fragments: a 700-bp *NdeI/HindIII* β -casein fragment isolated from *pS27*, the STII signal sequence, and a *NcoI/HindIII*-digested *pACAT7* vector.

The expression vectors *pS26* and *pS28* were used to transform *E. coli* strains *BL21(DE3)*, *BL21(DE3)pLysS*, and *BL21(DE3)pLysE*. The bacteria were grown in Luria Broth medium containing 50 μ g/ml carbenicillin, and when *BL21(DE3)pLysS* and *BL21(DE3)pLysE* were used the medium was supplemented with 25 μ g/ml chloramphenicol.

For induction of expression the cultures were grown to a density yielding an optical density (OD) of 0.6 at a wavelength of 600 nanometers (OD₆₀₀), then 0.4 mM IPTG was added to induce the T7 system. The cells were

harvested about 90 minutes after induction.

Recombinant β -casein was isolated using standard procedures. The inducible T7-based expression system resulted in high-level expression of recombinant β -casein. Bacteria were harvested and the cells pelleted by centrifugation. The supernatant contained the periplasmic proteins and the pellet the cytoplasmic fraction. The recombinant proteins obtained were compared with native β -casein, which had been purified by standard methods including either ion-exchange chromatography followed by reversed-phase HPLC or gel filtration. Recombinant and native β -casein were compared by standard biochemical techniques comprising SDS-PAGE, Western blotting, amino acid analysis, peptide mapping, phosphate analysis, and mass spectrometry. Recombinant β -casein expressed in *E.coli* was found to comigrate with full-length, nonphosphorylated native human β -casein, which is one of seven native isoforms.

Recombinant human β -casein has also been expressed in *S.cerevisiae* using the pYES 2.0 vector (Invitrogen Corp., San Diego, CA), but the expression level was approximately 10% of that obtained in *E.coli*. However, Hansson et al. found that *S. cerevisiae* appeared to express phosphorylated human milk β -casein.

β -Casein Hydrolysates

The human β -casein (both native and recombinant) was digested using the specific endoproteinase GLU-C (Sigma, sequencing grade) which catalyzes the hydrolysis of peptide bonds at the C-terminal of glutamic acid residue. After monitoring the digest using high pressure liquid chromatography, an enzyme to protein ratio of 1:100 (weight/weight) was chosen for a 30 hour digestion at 37°C in 0.1 M NH_4HCO_3 , pH 7.8. These digests were dried and resuspended in appropriate buffers prior to use in the assays discussed above.

INHIBITION OF HUMAN RSV INFECTION OF HEp-2 CELLS

The Long strain of RSV was grown in HEp-2 cells under Eagle minimal essential medium (MEM) with 2% fetal bovine serum (FBS). The virus was harvested at a cytopathic effect (CPE) of 3 to 4+, sonicated for 10 seconds at 50% power with a Microson ultrasonic bell disrupter (Heat Systems - Ultrasonics, Inc., Farmingdale, N.Y.), divided into portions and stored at -70°C. The same preparation of virus was used for a series of tests, but a fresh sample was used for each test run.

The neutralization tests were performed in 96-well, flat-bottomed, tissue culture, microtiter plates (catalog no. 3596; Costar, Cambridge, Mass.). Serum or a monoclonal antibody (MAb) in the form of ascites fluid, which had been heat inactivated at 56°C for 30 min., was added to duplicate wells and serial fourfold dilutions were performed in the microtiter plates. All dilutions were in MEM-2% FBS, and the final volume was 75 μ l per well. Approximately 60 50% tissue culture infective doses of virus in 25 μ l of MEM-2% FBS then were added to each well, and the mixture was incubated for 2 h at 4°C.

Approximately 15,000 HEp-2 cells in 100 μ l of MEM-5% FBS were added to each well, and the plates were wrapped in cellophane and incubated at 35.5°C in a humidified CO₂ incubator for 3 days. The plates were fixed by aspirating the contents of the wells, washing three times with phosphate-buffered saline (PBS) at pH 7.2 with 0.5% Tween 20, adding 75 μ l of an 80% (vol/vol) solution of acetone-PBS, and incubating for 15 min at 4°C. After the incubation period, the contents were aspirated, and the plates were air dried.

The Enzyme Linked Immuno Sorbent Assay (ELISA) was performed on the same day as the fixation, or the plates were stored overnight at 4°C and the ELISA was performed on the next day. For the ELISA, the wells were precoated with 200 μ l of PBS with 0.5% gelatin for 30 min at 35°C, the contents were aspirated, the wells were washed with PBS (pH 7.2)-0.5% Tween 20 and 75 μ l of bovine anti-RSV serum (BaRSV) Burroughs Wellcome Co., Research Triangle Park, N.C.) diluted in PBS 0.5% gelatin plus 0.5% Tween 20 and 2% normal goat serum was added and incubated for 1 hour at 35.5°C. The contents were aspirated, the wells were washed, and 75 μ l of peroxidase-conjugated, goat anti-bovine immunoglobulin G (IgG) (Kirkegaard and Perry

Laboratories, Inc., Gaithersburg, MD) diluted in PBS-0.5% gelatin-0.5% Tween 20-2% normal goat serum was added and incubated for 1 hour at 35.0°C. The contents of the wells were aspirated again, the wells were washed, and 125 μ l of substrate (0.4 mg of *o*-phenylenediamine dihydrochloride per ml 0.015% H₂O₂) in 0.15 M citrate phosphate buffer (pH 5.5) was added and incubated at room temperature for 40 to 45 min. The reaction was stopped with 3.5 M HCl, and the A₄₉₀ was read with a microplate reader. Each dilution of antibody was run in duplicate, and each plate included control wells with uninfected cells, a back titration, i.e. titration of the virus inoculum in MEM-2% FBS, and a titration of a preimmune or nonneutralizing antibody. An absorbance reading of greater than or equal to 3 standard deviations above the mean of 15 control wells was considered to be evidence of virus replication. The dilutions of BaRSV (1:1,000) and goat anti-bovine IgG (1:5,000) used through the study initially was determined by checkerboard titrations.

This assay was based upon the disclosure of Anderson et al., "Microneutralization Test for Respiratory Syncytial Virus Based on an Enzyme Immunoassay", JOURNAL OF CLINICAL MICROBIOLOGY, December 1985, pages 1050-1052.

RESULTS FROM HEp-2 CELL ASSAY

The human and bovine β -casein solutions were prepared first in 20 mM ethanalamine, 6 M urea, pH 9.5 and then washed twice in PBS by ultrafiltration using Centricon membrane filters (Amicon, MA) with a cut-off of 3,000 daltons. After resuspending in appropriate buffer for the HEp-2 cell assay described above, these samples were tested in the assay. Experiments with different designated numbers were performed in different days. As shown in Table 1, human β -casein caused an inhibition of infection/virus replication of 50% or more at concentrations of 0.4 mg/ml or greater. It should be noted than when referring to Table 1, a higher percent inhibition indicates a higher level of bioactivity of the "AGENT", and a lower percent inhibition indicates a lower level of activity of the "AGENT". Bovine β -casein was not significantly active even at 1.6 mg/ml. These results indicated that β -casein from human milk has different bioactivity compared to the bovine milk β -casein.

TABLE 1
INHIBITION OF HUMAN RSV INFECTION OF HEp-2 CELLS

<u>AGENT USED</u>	<u>CONC.</u> (mg/ml)	<u>PERCENT INHIBITION</u>
β -Casein Isolated from Human Milk	1.6	>90
	0.8	>90
	0.4	>90
Bovine β -casein	1.6	0
	0.8	0
	0.4	0

Data shown are average of three replicates.

INHIBITION OF HUMAN RSV INFECTION OF LLC-MK2 CELLS

The RSV inhibition assay quantitatively determines the ability of a test reagent (antibody or other bioactive compound) to inhibit the infection of monkey kidney cells (LLC-MK2) (ATCC CCL 7) in microtiter plates. Infected cells were identified using an immunoperoxidase method. The method is described briefly below.

LLC-MK2 cells were seeded into fibronectin treated Costar microtiter plates (5.0×10^3 cells per well) and incubated for 3-4 days prior to use in the infectivity reduction assay. On the day of assay, the Long strain of RSV was diluted in MEM to 10-20,000 infected cell units (ICU/mL), and added to an equal volume (200 μ L) of serially diluted sample preparations at suitable concentration (ex. 0.5, 1.0, and 2.0 mg casein/mL). Mixtures of diluted test samples and virus were then incubated for 2 hours at 4°C prior to adding to LLC-MK2 cells. Prior to addition of the diluted sample-virus mixtures to microtiter plates, culture medium was removed and the monolayers rinsed one time with MEM. All diluted sample-virus mixtures were tested in triplicate wells. The diluted sample-virus mixtures were allowed to absorb to LLC-MK2 monolayers for 2 hours at 37°C in a humidified CO₂ incubator. Following incubation, 150 μ l of MEM was added to all wells and the plates incubated at 37°C for 16 hours in the CO₂ incubator. After overnight incubation, the culture medium was removed and the monolayers fixed with cold ethanol. After fixing, microtiter plates were rinsed once with 200 μ l Dulbecco's PBS per well, and bovine anti-RSV antibody (200 μ l) was added to all wells. Following a 30 minute incubation at room temperature and three rinses with PBS/0.5% chick albumen (PBS/CEA), peroxidase labeled rabbit anti-bovine IgG was added to all wells and incubated at room temperature for 30 minutes. Microtiter plates were then rinsed 3 times with PBS/CEA and diaminobenzidine substrate added and incubated for 20 minutes. Plates were then rinsed as above with PBS/CEA, and the number of stained RSV-infected cells per well determined using an inverted microscope.

RESULTS FROM LLC-MK2 CELL ASSAY

The proteins described in Table 1 were also tested in this assay for inhibition of RSV infection. Results from this assay are shown in Table 2. Once again, native human milk β -casein was found to be active at concentrations of 1 mg/ml or greater while bovine β -casein was not significantly active. The GLU-C hydrolysates of both native and recombinant human β -casein were active at concentrations of 0.75 mg/ml and higher. Hence these results indicated that the recombinant human β -casein, native human β -casein and their hydrolysates inhibit RSV infection of both HEp-2 mammalian cells and LLC-MK2 mammalian cells.

TABLE 2

INHIBITION OF HUMAN RSV INFECTION OF LLC-MK2 CELLS

<u>AGENT USED</u>	<u>CONC.</u> (mg/ml)	<u>PERCENT INHIBITION</u>
β -Casein Isolated from Human Milk	1.5	87
	1	69
	0.75	33
	0.38	20
Bovine β -casein	1	21
	0.5	23
	0.25	6
Hydrolysate of β -casein Isolated from Human Milk	1.5	99
	0.75	77
	0.38	60
Hydrolysate of Recombinant Human β -Casein	1.5	84
	0.75	42
	0.38	25
GLU-C Enzyme Control	.025	64
	.0125	27
	.0068	19

Data shown are average of four replicates.

It has been concluded from the foregoing experiments that β -casein isolated from human milk, a recombinant form of the β -casein contained in human milk, and hydrolysates of both, inhibits the infection of mammalian cells by RSV. Furthermore, inasmuch as RSV has been identified in the literature as being associated with respiratory tract infection, it has been concluded that the above identified forms of human β -casein may be employed in the prevention and treatment of respiratory tract infection in humans, especially in human infants. In view of the therapeutic effect of enterally ingested human milk containing human β -casein upon respiratory tract infection, it is concluded that the above identified forms of human β -casein have a therapeutic benefit when enterally (orally) ingested.

The therapeutic effects described in the preceding paragraph may be provided by an enteral liquid nutritional product, such as infant formula, comprising one or more proteins not contained in human milk in combination with a therapeutically effective amount of at least one of the forms of human β -casein described in the preceding paragraph. It is further concluded that the infection of mammalian cells by RSV may be inhibited by administering via a nasal passageway, or as a throat spray, a formulation containing a therapeutically effective amount of at least one of the forms of human β -casein identified in the preceding paragraph. Such a nasally administered formulation may be in the form of either drops or a spray.

The enteral nutritional, throat spray and nasal products and methods are believed to be effective in inhibiting the infection of mammalian cells by RSV because the interaction of the human β -casein and RSV is believed to occur via direct contact rather than following digestion and absorption of the β -casein.

It is believed that the above identified forms of human β -casein may be incorporated into any standard or specialized enteral liquid nutritional product containing at least one protein not found in human milk, such as bovine milk based or soy based infant formulas, and other beverages consumed by young children. In a preferred embodiment no proteins or hydrolysates thereof found in human milk, other than β -casein, are contained in the liquid enteral nutritional product. Such a product has utility in the treatment and prevention of respiratory tract infection in human infants.

While preferred embodiments of the invention have been disclosed, it will be apparent to those skilled in the art that various changes and

modifications may be made therein without deviating from the spirit or scope of this invention.

SEQUENCE LISTING**(1) GENERAL INFORMATION:**

- (i) **APPLICANT:** Abbott Laboratories
- (ii) **TITLE OF INVENTION:** Inhibition of Infection of Mammalian Cells by Respiratory Syncytial Virus

- (iii) **NUMBER OF SEQUENCES:** 5

- (iv) **CORRESPONDENCE ADDRESS:**

(A) **ADDRESSEE:** Lonnie R. Drayer
ROSS Products Division
Abbott Laboratories

(B) **STREET:** 625 Cleveland Avenue

(C) **CITY:** Columbus

(D) **STATE:** Ohio

(E) **COUNTRY:** United States of America

(F) **ZIP:** 43215

- (v) **COMPUTER READABLE FORM:**

(A) **MEDIUM TYPE:** Diskette, 3.5 inch, 1.44 Mb storage

(B) **COMPUTER:** IBM Compatible

(C) **OPERATING SYSTEM:** MS-DOS Version 6.21

(D) **SOFTWARE:** WordPerfect Version 6.0a

- (vi) **CURRENT APPLICATION DATA:**

(A) **APPLICATION NUMBER:**

(B) **FILING DATE:**

(C) **CLASSIFICATION:**

- (vii) **PRIOR APPLICATION DATA:**

(A) APPLICATION NUMBER: US 08/249,554

(B) FILING DATE: 26-MAY-1994

(A) APPLICATION NUMBER: US 08/249,555

(B) FILING DATE: 26-MAY-1994

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (614) 624-3774

(B) TELEFAX: (614) 624-3074

(C) TELEX: None

(2) INFORMATION FOR SEQ ID NO: 1

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1065 base pairs

(B) TYPE: Nucleic acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Unknown

(ii) MOLECULE TYPE: Cloned cDNA representing the product of a human genomic DNA segment

(A) DESCRIPTION: Human milk β eta-casein

(iii) HYPOTHETICAL:

(iv) ANTI-SENSE:

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE: Human

(A) ORGANISM: Homo sapiens

(B) STRAIN:

(C) INDIVIDUAL ISOLATE:

- (D) DEVELOPMENTAL STAGE: Adult
- (E) HAPLOTYPE:
- (F) TISSUE TYPE: Mammary gland
- (G) CELL TYPE:
- (H) CELL LINE:
- (I) ORGANELLE:
- (vii) IMMEDIATE SOURCE: Human Mammary Gland
 - (A) LIBRARY:
 - (B) CLONE:
- (viii) POSITION IN GENOME:
 - (A) CHROMOSOME SEGMENT:
 - (B) MAP POSITION:
 - (C) UNITS:
- (ix) FEATURE:
 - (A) NAME/KEY:
 - (B) LOCATION:
 - (C) IDENTIFICATION METHOD: DNA sequencing and restriction analysis
 - (D) OTHER INFORMATION: The encoded product of nucleotide SEQ ID NO: 1 is the human milk protein, β -casein.
- (x) PUBLICATION INFORMATION:
 - (A) AUTHORS: B. Lonnerdal, et al.
 - (B) TITLE: Cloning and sequencing of a cDNA encoding human milk beta-casein.
 - (C) JOURNAL: Federation European Biochemical Society Letters
 - (D) VOLUME: 269

- (E) ISSUE:
- (F) PAGES: 153 - 156
- (G) DATE: 1990
- (H) DOCUMENT NUMBER:
- (I) FILING DATE:
- (J) PUBLICATION DATE:
- (K) RELEVANT RESIDUES:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1

CGG	ATG	AAG	GTC	CTC	ATC	CTC	GCC	TGC	CTG	GTG	GCT	CTT	GCT	CTT	45
GCA	AGG	GAG	ACC	ATA	GAA	AGC	CTT	TCA	AGC	AGT	GAG	GAA	TCT	ATT	90
ACA	GAA	TAC	AAG	AAA	GTT	GAG	AAG	GTT	AAA	CAT	GAG	GAC	CAG	CAG	135
CAA	GGA	GAG	GAT	GAA	CAC	CAG	GAT	AAA	ATC	TAC	CCC	TCT	TTC	CAG	180
CCA	CAG	CCT	CTG	ATC	TAT	CCA	TTC	GTT	GAA	CCT	ATC	CCC	TAT	GGT	225
TTT	CTT	CCA	CAA	AAC	ATT	CTG	CCT	CTT	GCT	CAG	CCT	GCT	GTG	GTG	270
CTG	CCT	GTC	CCT	CAG	CCT	GAA	ATA	ATG	GAA	GTC	CCT	AAA	GCT	AAA	315
GAC	ACT	GTC	TAC	ACT	AAG	GGC	AGA	GTG	ATG	CCT	GTC	CTT	AAA	TCT	360
CCA	ACG	ATA	CCC	TTT	TTT	GAC	CCT	CAA	ATC	CCA	AAA	CTC	ACT	GAT	405
CTT	GAA	AAT	CTG	CAT	CTT	CCT	CTG	CCT	CTG	CTC	CAG	CCC	TTG	ATG	450
CAG	CAG	GTC	CCT	CAG	CCT	ATT	CCT	CAG	ACT	CTT	GCA	CTT	CCC	CCT	495
CAG	CCC	CTG	TGG	TCT	GTT	CCT	CAG	CCC	AAA	GTC	CTG	CCT	ATC	CCC	540
CAG	CAA	GTG	GTG	CCC	TAC	CCT	CAG	AGA	GCT	GTG	CCT	GTT	CAA	GCC	585
CTT	CTG	CTC	AAC	CAA	GAA	CTT	CTA	CTT	AAC	CCC	ACC	CAC	CAG	ATC	630
TAC	CCT	GTG	ACT	CAG	CCA	CTT	GCC	CCA	GTT	CAT	AAC	CCC	ATT	AGT	675
GTC	TAA	GAA	GAT	TTC	AAA	GTT	AAT	TTT	CCC	TCC	TTA	TTT	TTG	AAT	720
TGA	CTG	AGA	CTG	GAA	ATA	TGA	TGC	CTT	TTC	CGT	CTT	TGT	ATC	ACG	765
TTA	CCC	CAA	ATT	AAG	TAT	GTT	TGA	ATG	AGT	TTA	TAT	GGA	AAA	AAT	810
GAA	CTT	TGT	CCC	TTT	ATT	TAT	TTT	ATA	TAT	TAT	GTC	ATT	CAT	TTA	855
ATT	TGA	AAT	TTG	ACT	CAT	GAA	CTA	TTT	ACA	TTT	TCC	AAA	TCT	TAA	900
TTC	AAC	TAG	TAC	CAC	AGA	AGT	TCA	ATA	CTC	ATT	TGG	AAA	TGC	TAC	945
AAA	CAT	ATC	AAA	CAT	ATG	TAT	ACA	AAT	TGT	TTC	TGG	AAT	TGT	GCT	990
TAT	TTT	TAT	TTC	TTT	AAG	AAT	CTA	TTT	CCT	TTC	CAG	TCA	TTT	CAA	1035
TAA	ATT	ATT	CTT	AAG	CAT	AAA	AAA	AAA	AAA						1065

(2) INFORMATION FOR SEQ ID NO: 2

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 105 base pairs

- (B) TYPE: Nucleic acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Unknown
- (ii) MOLECULE TYPE: Synthetic oligonucleotide
 - (A) DESCRIPTION:
 - (iii) HYPOTHETICAL:
 - (iv) ANTI-SENSE:
 - (v) FRAGMENT TYPE:
 - (vi) ORIGINAL SOURCE: Synthetic Oligonucleotide Sequence
 - (A) ORGANISM:
 - (B) STRAIN:
 - (C) INDIVIDUAL ISOLATE:
 - (D) DEVELOPMENTAL STAGE:
 - (E) HAPLOTYPE:
 - (F) TISSUE TYPE:
 - (G) CELL TYPE:
 - (H) CELL LINE:
 - (I) ORGANELLE:
 - (vii) IMMEDIATE SOURCE:
 - (A) LIBRARY:
 - (B) CLONE:
 - (viii) POSITION IN GENOME:
 - (A) CHROMOSOME/SEGMENT:
 - (B) MAP POSITION:

(C) UNITS:

(ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION:

(C) IDENTIFICATION METHOD: DNA sequencing and restriction analysis

(D) OTHER INFORMATION: The synthetic oligonucleotide assures adaptation of translation sequence to *E. coli* codon usage.

(x) PUBLICATION INFORMATION:

(A) AUTHORS: L. Hansson, et al.

(B) TITLE: Expression of Human Milk β -casein in *Escherichia coli*: Comparison of Recombinant Protein with Native Isoforms.

(C) JOURNAL: Protein Expression and Purification

(D) VOLUME: 4

(E) ISSUE:

(F) PAGES: 373 - 381

(G) DATE: 1993

(H) DOCUMENT NUMBER:

(I) FILING DATE:

(J) PUBLICATION DATE:

(K) RELEVANT RESIDUES:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2

CTG CAG AAT TCA TAT GCG TGA AAC CAT CGA ATC CCT GAG CTC GAG	45
CGA AGA ATC GAT CAC CGA ATA CAA AAA AGT TGA AAA AGT TAA ACA	90
CGA GGA CCA GGA TCC	105

(2) INFORMATION FOR SEQ ID NO: 3

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 71 base pairs
- (B) TYPE: Nucleic acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Unknown

(ii) MOLECULE TYPE: Synthetic oligonucleotide

- (A) DESCRIPTION:

(iii) HYPOTHETICAL:

(iv) ANTI-SENSE:

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE: Synthetic Oligonucleotide Sequence

- (A) ORGANISM:
- (B) STRAIN:
- (C) INDIVIDUAL ISOLATE:
- (D) DEVELOPMENTAL STAGE:
- (E) HAPLOTYPE:
- (F) TISSUE TYPE:
- (G) CELL TYPE:
- (H) CELL LINE:
- (I) ORGANELLE:

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY:
- (B) CLONE:

(viii) POSITION IN GENOME:

- (A) CHROMOSOME/SEGMENT:

(B) MAP POSITION:

(C) UNITS:

(ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION:

(C) IDENTIFICATION METHOD: DNA sequencing and restriction analysis

(D) OTHER INFORMATION: The synthetic oligonucleotide encodes the carboxy-terminal end and translation stop.

(x) PUBLICATION INFORMATION:

(A) AUTHORS: L. Hansson, et al.

(B) TITLE: Expression of Human Milk β -casein in Escherichia coli: Comparison of Recombinant Protein with Native Isoforms.

(C) JOURNAL: Protein Expression and Purification

(D) VOLUME: 4

(E) ISSUE:

(F) PAGES: 373 - 381

(G) DATE: 1993

(H) DOCUMENT NUMBER:

(I) FILING DATE:

(J) PUBLICATION DATE:

(K) RELEVANT RESIDUES:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3

AGA TCT ACC CTG TGA CTC AGC CAC TTG CCC CAG TTC ATA ACC CCA 45
TTA GTG TCT AAT AAG GAT CCG AAT TC 71

(2) INFORMATION FOR SEQ ID NO: 4

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 68 base pairs
 - (B) TYPE: Nucleic acid
 - (C) STRANDEDNESS: Single
 - (D) TOPOLOGY: Unknown
- (ii) MOLECULE TYPE: Synthetic oligonucleotide
 - (A) DESCRIPTION:
- (iii) HYPOTHETICAL:
- (iv) ANTI-SENSE:
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE: Synthetic Oligonucleotide Sequence
 - (A) ORGANISM:
 - (B) STRAIN:
 - (C) INDIVIDUAL ISOLATE:
 - (D) DEVELOPMENTAL STAGE:
 - (E) HAPLOTYPE:
 - (F) TISSUE TYPE:
 - (G) CELL TYPE:
 - (H) CELL LINE:
 - (I) ORGANELLE:
- (vii) IMMEDIATE SOURCE:
 - (A) LIBRARY:
 - (B) CLONE:
- (viii) POSITION IN GENOME:

- (A) CHROMOSOME SEGMENT:
- (B) MAP POSITION:
- (C) UNITS:
- (ix) FEATURE:
 - (A) NAME/KEY:
 - (B) LOCATION:
 - (C) IDENTIFICATION METHOD: DNA sequencing and restriction analysis
 - (D) OTHER INFORMATION: Modified enterotoxin STII signal sequence.
- (x) PUBLICATION INFORMATION:
 - (A) AUTHORS: L. Hansson, et al.
 - (B) TITLE: Expression of Human Milk β -casein in Escherichia coli: Comparison of Recombinant Protein with Native Isoforms.
 - (C) JOURNAL: Protein Expression and Purification
 - (D) VOLUME: 4
 - (E) ISSUE:
 - (F) PAGES: 373 - 381
 - (G) DATE: 1993
 - (H) DOCUMENT NUMBER:
 - (I) FILING DATE:
 - (J) PUBLICATION DATE:
 - (K) RELEVANT RESIDUES:
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4

CAT GAA AAA GAA TAT CGC ATT TCT TCT TGC ATC GAT GTT CGT TTT
TTC TAT TGC TAC AAA TGC ATA TG

45

68

(2) INFORMATION FOR SEQ ID NO: 5

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 base pairs
- (B) TYPE: Nucleic acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Unknown

(ii) MOLECULE TYPE: Synthetic oligonucleotide

- (A) DESCRIPTION:

(iii) HYPOTHETICAL:

(iv) ANTI-SENSE:

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE: Synthetic Oligonucleotide Sequence

- (A) ORGANISM:

- (B) STRAIN:

- (C) INDIVIDUAL ISOLATE:

- (D) DEVELOPMENTAL STAGE:

- (E) HAPLOTYPE:

- (F) TISSUE TYPE:

- (G) CELL TYPE:

- (H) CELL LINE:

- (I) ORGANELLE:

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY:

- (B) CLONE:

(viii) POSITION IN GENOME:

- (A) CHROMOSOME SEGMENT:
- (B) MAP POSITION:
- (C) UNITS:
- (ix) FEATURE:
 - (A) NAME/KEY:
 - (B) LOCATION:
 - (C) IDENTIFICATION METHOD: DNA sequencing and restriction analysis
 - (D) OTHER INFORMATION:
- (x) PUBLICATION INFORMATION:
 - (A) AUTHORS: L. Hansson, et al.
 - (B) TITLE: Expression of Human Milk β -casein in Escherichia coli: Comparison of Recombinant Protein with Native Isoforms.
 - (C) JOURNAL: Protein Expression and Purification
 - (D) VOLUME: 4
 - (E) ISSUE:
 - (F) PAGES: 373 - 381
 - (G) DATE: 1993
 - (H) DOCUMENT NUMBER:
 - (I) FILING DATE:
 - (J) PUBLICATION DATE:
 - (K) RELEVANT RESIDUES:
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5

CLAIMS:

1. A liquid enteral nutritional product comprising at least one protein not contained in human milk in combination with at least one material selected from the group consisting of β -casein isolated from human milk, a recombinant form of the β -casein contained in human milk and hydrolysates of both in a therapeutically effective amount which inhibits the infection of mammalian cells by RSV.
2. A liquid enteral nutritional product according to claim 1 wherein the product is an infant formula.
3. A liquid enteral nutritional infant formula comprising at least one protein not contained in human milk in combination with at least one material selected from the group consisting of β -casein isolated from human milk, a recombinant form of the β -casein contained in human milk and hydrolysates of both in a therapeutically effective amount which inhibits the infection of mammalian cells by RSV, said infant formula containing no other proteins which are found in human milk.
4. A nasally administrable formulation comprising at least one material selected from the group consisting of β -casein isolated from human milk, a recombinant form of the β -casein contained in human milk and hydrolysates of both in a therapeutically effective amount which inhibits the infection of mammalian cells by RSV.
5. A throat spray formulation comprising at least one material selected from the group consisting of β -casein isolated from human milk, a recombinant form of the β -casein contained in human milk and hydrolysates of both in a therapeutically effective amount which inhibits the infection of mammalian cells by RSV.
6. A method of inhibiting the infection of mammalian cells by RSV by enterally ingesting a liquid nutritional product comprising at least one protein not contained in human milk in combination with a therapeutically effective amount of at least one material selected from the group consisting

of β -casein isolated from human milk, a recombinant form of the β -casein contained in human milk and hydrolysates of both.

7. A method of inhibiting the infection of mammalian cells by *RSV* in a human infant by enterally feeding to said human infant an infant formula comprising at least one protein not contained in human milk in combination with a therapeutically effective amount of at least one material selected from the group consisting of β -casein isolated from human milk, a recombinant form of the β -casein contained in human milk and hydrolysates of both.

8. A method of treating and preventing respiratory tract infection in a human by inhibiting the infection of mammalian cells by *RSV* by feeding to said human an enteral nutritional product comprising at least one protein not contained in human milk in combination with a therapeutically effective amount of at least one material selected from the group consisting of β -casein isolated from human milk, a recombinant form of the β -casein contained in human milk and hydrolysates of both.

9. A method of treating and preventing respiratory tract infection in a human infant by inhibiting the infection of mammalian cells by *RSV* by feeding to said human infant an enteral formula comprising at least one protein not contained in human milk in combination with a therapeutically effective amount of at least one material selected from the group consisting of β -casein isolated from human milk, a recombinant form of the β -casein contained in human milk and hydrolysates of both.

10. A method of inhibiting the infection of mammalian cells by *RSV* by administering via a nasal passageway a formulation containing a therapeutically effective amount of at least one material selected from the group consisting of β -casein isolated from human milk, a recombinant form of the β -casein contained in human milk and hydrolysates of both.

11. A method of inhibiting the infection of mammalian cells by *RSV* by administering a throat spray formulation containing a therapeutically effective amount of at least one material selected from the group consisting

of β -casein isolated from human milk, a recombinant form of the β -casein contained in human milk and hydrolysates of both.

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/US 95/03628

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K38/17 A23L1/305 C07K14/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,91 06308 (B.ANDERSSON ET AL.) 16 May 1991 cited in the application see the whole document ---	1-11
X	EP,A,0 291 265 (SNOW BRAND MILK PRODUCTS CO. LTD.) 17 November 1988 see claims 1-7 ---	1-11
A	MICROB.PATHOG., vol.8, no.5, May 1990 pages 315 - 323 G.ANIANSSON ET AL. 'Anti-adhesive activity of human casein against Streptococcus pneumoniae and Haemophilus influenzae' cited in the application see the whole document ---	1-11 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *'A' document defining the general state of the art which is not considered to be of particular relevance
- *'E' earlier document but published on or after the international filing date
- *'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *'O' document referring to an oral disclosure, use, exhibition or other means
- *'P' document published prior to the international filing date but later than the priority date claimed

*'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

*'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

*'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

*'&' document member of the same patent family

1

Date of the actual completion of the international search

24 July 1995

Date of mailing of the international search report

08.08.95

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Theuns, H

INTERNATIONAL SEARCH REPORT

Inten ial Application No
PCT/US 95/03628

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ADV. EXP. MED. BIOL., vol. 310, 1991 pages 167 - 171 C. SVANBORG ET AL. 'ANTI-ADHESIVE MOLECULES IN HUMAN MILK' see the whole document ---	1-11
X	WO,A,91 08675 (C.W.SLATTERY ET AL.) 27 June 1991 see page 1 - page 3 ---	1-5
X	WO,A,94 06306 (NEW ZEALAND DAIRY RESEARCH INSTITUTE) 31 March 1994 see claims 38,39 ---	1-5
X	WO,A,93 04171 (SYMBICOM AKTIEBOLAG) 4 March 1993 see claims 40-44 ---	1-5
X	WO,A,93 04172 (SYMBICOM AKTIEBOLAG) 4 March 1993 see page 37 - page 42 -----	1-5

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/03628

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9106308	16-05-91	SE-B-	465109	29-07-91
		AU-B-	633647	04-02-93
		AU-A-	6647090	31-05-91
		EP-A-	0454813	06-11-91
		JP-T-	4503077	04-06-92
		SE-A-	8903625	01-05-91
EP-A-0291265	17-11-88	JP-A-	63284133	21-11-88
		US-A-	5147853	15-09-92
		US-A-	5344820	06-09-94
WO-A-9108675	27-06-91	AU-A-	7177391	18-07-91
WO-A-9406306	31-03-94	AU-B-	4987393	12-04-94
		EP-A-	0661927	12-07-95
WO-A-9304171	04-03-93	WO-A-	9304172	04-03-93
		EP-A-	0599978	08-06-94
WO-A-9304172	04-03-93	WO-A-	9304171	04-03-93
		EP-A-	0599978	08-06-94

INTERNATIONAL SEARCH REPORT

Int. application No.

PCT/US 95/03628

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 6-11 are directed to a method of treatment of the

human/animal body the search has been based on the alleged effects of the compound/composition.

2. Claims Nos.:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.